MYELOPROLIFERATIVE DISORDERS
Clinical trials for MYELOPROLIFERATIVE DISORDERS explained in plain language.
Never miss a new study
Get alerted when new MYELOPROLIFERATIVE DISORDERS trials appear
Sign up with your email to follow new studies for MYELOPROLIFERATIVE DISORDERS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New transplant technique aims to tame Graft-Versus-Host disease
Disease control OngoingThis early-phase study tests a new way to do stem cell transplants for people with advanced blood cancers like leukemia. Instead of using strong drugs to prevent complications, doctors add special immune cells (regulatory T-cells) to the transplant to help the body accept the new…
Matched conditions: MYELOPROLIFERATIVE DISORDERS
Phase: PHASE1 • Sponsor: Stanford University • Aim: Disease control
Last updated May 26, 2026 07:55 UTC
-
New drug may reduce dangerous side effects of stem cell transplants in older patients
Disease control OngoingThis early-phase study tests whether the drug itacitinib can prevent a serious complication called cytokine release syndrome (CRS) after a stem cell transplant in people aged 60 and older with blood cancers. The study involves 32 participants who receive a 'mini' transplant from …
Matched conditions: MYELOPROLIFERATIVE DISORDERS
Phase: PHASE1 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated May 18, 2026 12:03 UTC
-
Massive study seeks root causes of blood cancers
Knowledge-focused ENROLLING_BY_INVITATIONThis study aims to uncover the genetic causes of blood and bone marrow cancers by analyzing samples from 5,000 participants. Researchers will look for specific cell abnormalities that drive cancer growth and test whether existing drugs can reverse them. The goal is to develop gen…
Matched conditions: MYELOPROLIFERATIVE DISORDERS
Sponsor: OHSU Knight Cancer Institute • Aim: Knowledge-focused
Last updated May 22, 2026 13:50 UTC